<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cardiol Ther</journal-id><journal-title-group><journal-title>Cardiology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8261</issn><issn pub-type="epub">2193-6544</issn><publisher><publisher-name>Springer Healthcare Communications</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25135157</article-id><article-id pub-id-type="pmc">4107441</article-id><article-id pub-id-type="publisher-id">3</article-id><article-id pub-id-type="doi">10.1007/s40119-012-0003-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Comparison of Circumferential Pulmonary Vein Isolation and Antiarrhythmic Drug Therapy in Patients with Atrial Fibrillation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Xu</surname><given-names>Yanmin</given-names></name><address><email>xuyanmin@eyou.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Deepak</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Fawang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Guangping</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Gang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Cardiovascular Institute of Tianjin, 23 Ping Jiang Road, He Xi District, Tianjin, China </aff><aff id="Aff2"><label/>Tianjin Medical University, Tianjin, China </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>9</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>9</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2012</year></pub-date><volume>1</volume><issue>1</issue><elocation-id>3</elocation-id><history><date date-type="received"><day>28</day><month>6</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012</copyright-statement></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>The aim of this study was to evaluate quality of life after circumferential pulmonary vein isolation (CPVI) compared with antiarrhythmic drug therapy (ADT) in treating atrial fibrillation (AF). CPVI is now a common therapy in AF, but few studies have focused on the effect of CPVI on quality of life.</p></sec><sec><title>Methods</title><p>A total of 123 AF patients were followed prospectively. Quality of life was evaluated comparing CPVI with ADT as a second-line treatment for patients with AF. The Medical Outcomes Study Short Form (SF)-36 health surveys were conducted to establish a baseline score before initiation and again at 6&#x000a0;months after the intervention.</p></sec><sec><title>Results</title><p>Mean follow-up duration was 12.7&#x000a0;&#x000b1;&#x000a0;4.3&#x000a0;months. Of 123 patients enrolled, 66 were randomized to receive CPVI and 57 to ADT alone. At the 6-month follow-up, 13 (22.8%) patients in the ADT group and 41 (62.1%) patients in the CPVI group had no recurrence of AF. The SF-36 scales were significantly higher in the CPVI than in the ADT group, as were the physical component summary scores (269.3&#x000a0;&#x000b1;&#x000a0;58.6 vs. 234.9&#x000a0;&#x000b1;&#x000a0;66.9) and mental component summary scores (273.6&#x000a0;&#x000b1;&#x000a0;69.4 vs. 234.1&#x000a0;&#x000b1;&#x000a0;44.7). Quality of life was significantly higher in the CPVI group (except for body pain).</p></sec><sec><title>Conclusion</title><p>In patients with AF, CPVI has superiority over ADT with regards to the maintenance of sinus rhythm and improvements in quality of life.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Circumferential pulmonary vein isolation</kwd><kwd>Antiarrhythmic drug therapy</kwd><kwd>Atrial fibrillation</kwd><kwd>Quality of life</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The prevalence has been increasing with the aging population and the growing number of individuals who survive with chronic cardiovascular diseases. AF increases the risk of stroke and other embolic events, and has been associated with diminished functional status and heart failure symptoms of diastolic dysfunction with the development of dilated cardiomyopathy. It considerably impairs the patients&#x02019; quality of life (QoL). The technique of circumferential pulmonary vein isolation (CPVI) has undergone rapid evolution and has emerged as an important strategy in the treatment of patients with AF, although its effect on QoL has not been fully characterized. The aim of the present study was to evaluate effect on QoL score in patients with AF after treatment with CPVI compared with antiarrhythmic drug therapy (ADT).</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec3"><title>Patients</title><p>The study included 123 patients with AF, randomized to CPVI (<italic>n</italic>&#x000a0;=&#x000a0;66) or ADT alone (<italic>n</italic>&#x000a0;=&#x000a0;57). All patients were followed-up for 6&#x000a0;months after the intervention.</p></sec><sec id="Sec4"><title>QoL Assessment</title><p>QoL was assessed using the Medical Outcomes Study Short Form-36 (SF-36) health survey questionnaire [<xref ref-type="bibr" rid="CR1">1</xref>]. The SF-36 assesses eight specific QoL domains. It contains items to assess physical health (general health perception, physical functioning, role limitations due to physical problems, and bodily pain) and mental health (social functioning, role limitations due to emotional problems, mental health, and vitality). The total score from the eight scales can range from 0 to 100, with higher scores representing better functioning and QoL than lower scores.</p></sec><sec id="Sec5"><title>CPVI</title><p>The right internal jugular vein or subclavian vein was punctured while patients were under local anesthesia (lidocaine). An electrode catheter was introduced into the coronary sinus to record left atrial electrical activity and pacing. The intra-atrial septum was punctured under X-ray guidance projected into a SWARTZ L1 and R0 expansion scabbard along the sheath pipe into the ablation catheter infused with a cold saline catheter (St. Jude, USA) and LASSO catheter (St. Jude, USA). Under X-ray guidance and the EnSite3000 noncontact mapping system, three-dimensional (3D) electro-anatomic maps were constructed. The left and right pulmonary veins were encircled, with additional lines in the posterior left atrium or roof and along the mitral isthmus for those who had atrial flutter. Contiguous applications of radiofrequency energy were delivered at a target temperature of 50&#x02013;60&#x000b0;C and a maximal power output of 40&#x02013;50&#x000a0;W. The endpoint of ablation was an 80% reduction in the amplitude of the electrogram or a total of 40&#x000a0;s of energy application. Additional ablation was performed in the outer pulmonary veins, where the local electrogram amplitude exceeded 0.2&#x000a0;mV. If AF was still present at the end of circumferential pulmonary vein ablation, either amiodarone or transthoracic cardioversion was used to restore sinus rhythm.</p></sec><sec id="Sec6"><title>Follow-Up and Study Objectives</title><p>All patients were systematically followed up for 6&#x000a0;months after the intervention, with the following parametric data obtained: 12-lead electrocardiography (ECG), echocardiography, and 24-h Holter recording at baseline and 1, 3, and 6&#x000a0;months. Additional 12-lead ECG or a Holter measurement was encouraged when patients experienced palpitations. QoL was assessed using the SF-36 survey at baseline and again at 6&#x000a0;months after the intervention. Episodes were qualified as AF, if they lasted at least 3&#x000a0;min and were documented by ECG/Holter or reported by the patient as AF, even in the absence of ECG confirmation.</p></sec><sec id="Sec7"><title>Statistical Analysis</title><p>Analysis was carried out using SAS 16.0 statistical software package. Continuous variables were summarized by mean&#x000a0;&#x000b1;&#x000a0;standard deviation or the median and interquartile range (25th and 75th percentiles), and were compared using <italic>t</italic>-tests or Wilcoxon rank sum test. Categorical variables were represented by frequencies and percentages, and were compared using &#x003c7;<sup>2</sup> tests. Differences were considered significant at <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Clinical Characteristics</title><p>Clinical characteristics of 123 enrolled patients are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Sixty-six patients underwent CPVI (45 males and 21 females with the mean age of 61.5&#x000a0;&#x000b1;&#x000a0;10.1&#x000a0;years). Fifty-seven patients received ADT (35 males and 22 females with the mean age of 60.9&#x000a0;&#x000b1;&#x000a0;13.7&#x000a0;years). The baseline characteristics were comparable, with no significant differences between two groups (e.g., age, gender, paroxysmal AF or persistent AF, coronary artery disease, hypertension, and valvular heart disease; Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline patient characteristics between circumferential pulmonary vein isolation (CPVI) and antiarrhythmic drug therapy (ADT) group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Group</th><th align="left" rowspan="2">Age (years)</th><th align="left" rowspan="2">Total AF duration (years)</th><th align="left" colspan="3">Echocardiography</th><th align="left" rowspan="2">Mean rate</th></tr><tr><th align="left">LA (mm)</th><th align="left">LV (mm)</th><th align="left">EF</th></tr></thead><tbody><tr><td align="left">CPVI (<italic>n</italic>&#x000a0;=&#x000a0;66)</td><td align="left">61.5&#x000a0;&#x000b1;&#x000a0;10.1</td><td align="left">6.2&#x000a0;&#x000b1;&#x000a0;5.6</td><td align="left">39.2&#x000a0;&#x000b1;&#x000a0;5.6</td><td align="left">46.4&#x000a0;&#x000b1;&#x000a0;4.9</td><td align="left">58.5&#x000a0;&#x000b1;&#x000a0;7.4</td><td align="left">75.9&#x000a0;&#x000b1;&#x000a0;19.3</td></tr><tr><td align="left">ADT (<italic>n</italic>&#x000a0;=&#x000a0;57)</td><td align="left">60.9&#x000a0;&#x000b1;&#x000a0;13.7</td><td align="left">4.6&#x000a0;&#x000b1;&#x000a0;6.2</td><td align="left">39.1&#x000a0;&#x000b1;&#x000a0;5.9</td><td align="left">47.5&#x000a0;&#x000b1;&#x000a0;6.4</td><td align="left">58.1&#x000a0;&#x000b1;&#x000a0;6.2</td><td align="left">74.1&#x000a0;&#x000b1;&#x000a0;20.1</td></tr><tr><td align="left">
<italic>t</italic>-value</td><td align="left">0.27</td><td align="left">1.51</td><td align="left">0.12</td><td align="left">1.04</td><td align="left">0.36</td><td align="left">0.51</td></tr><tr><td align="left">
<italic>P</italic>-value</td><td align="left">0.79</td><td align="left">0.14</td><td align="left">0.91</td><td align="left">0.91</td><td align="left">0.30</td><td align="left">0.61</td></tr></tbody></table><table-wrap-foot><p>
<italic>AF</italic> atrial fibrillation, <italic>EF</italic> ejection fraction, <italic>LA</italic> left arterial, <italic>LV</italic> left ventricular</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Baseline patient characteristics between circumferential pulmonary vein isolation (CPVI) and antiarrhythmic drug therapy (ADT) group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Male, <italic>n</italic> (%)</th><th align="left" rowspan="2">Hypertension, <italic>n</italic> (%)</th><th align="left" rowspan="2">Diabetes mellitus, <italic>n</italic> (%)</th><th align="left" rowspan="2">Stroke, <italic>n</italic> (%)</th><th align="left" colspan="2">Type of AF</th><th align="left" colspan="3">Underlying disease</th></tr><tr><th align="left">Paroxysmal, <italic>n</italic> (%)</th><th align="left">Persistent, <italic>n</italic> (%)</th><th align="left">CHD, <italic>n</italic> (%)</th><th align="left">HC, <italic>n</italic> (%)</th><th align="left">VHD, <italic>n</italic> (%)</th></tr></thead><tbody><tr><td align="left">CPVI</td><td align="left">45 (68.1)</td><td align="left">27 (40.9)</td><td align="left">8 (12.1)</td><td align="left">5 (7.6)</td><td align="left">60 (90.9)</td><td align="left">6 (9.1)</td><td align="left">21 (37.5)</td><td align="left">3 (4.5)</td><td align="left">3 (4.5)</td></tr><tr><td align="left">ADT</td><td align="left">35 (61.4)</td><td align="left">20 (35.1)</td><td align="left">13 (22.8)</td><td align="left">6 (10.5)</td><td align="left">50 (87.7)</td><td align="left">7 (12.3)</td><td align="left">28 (49.1)</td><td align="left">4 (7.0)</td><td align="left">2 (3.5)</td></tr><tr><td align="left">&#x003c7;<sup>2</sup>-value</td><td align="left">0.62</td><td align="left">0.44</td><td align="left">0.47</td><td align="left">0.33</td><td align="left" colspan="2">0.33</td><td align="left" colspan="3">4.84</td></tr><tr><td align="left">
<italic>P</italic>-value</td><td align="left">0.43</td><td align="left">0.51</td><td align="left">0.12</td><td align="left">0.57</td><td align="left" colspan="2">0.57</td><td align="left" colspan="3">0.39</td></tr></tbody></table><table-wrap-foot><p>
<italic>AF</italic> atrial fibrilation, <italic>CHD</italic> coronary heart disease, <italic>HC</italic> hypertensive cardiopathy, <italic>VHD</italic> valvular heart disease</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>QoL at Baseline and at Follow-up</title><p>A total of 123 patients were prospectively followed up for 6&#x000a0;months. At the 6-month follow-up 13 (22.8%) patients in the ADT group and 41 (62.1%) patients in the CPVI group had no recurrence of AF. At baseline, there were no significant differences in QoL between the ADT and CPVI groups. Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows the changes in QoL from baseline to the 6-month follow-up assessment for the SF-36 scales pertaining to physical and mental health in the CPVI group. For all scales the observation was statistically significant different in the CPVI group at baseline vs. 6&#x000a0;months (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), For seven of eight scales (except for body pain), the observation was statistically significant at baseline vs. 6&#x000a0;months in the CPVI group. The 6-month physical component summary (PCS) and mental component summary (MCS) scores were increased significantly in the CPVI group to 269.3&#x000a0;&#x000b1;&#x000a0;58.6 and 273.6&#x000a0;&#x000b1;&#x000a0;69.4, respectively (within-group <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 for both; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In the ADT group, the PCS and MCS scores also increased at 6&#x000a0;months to 234.9&#x000a0;&#x000b1;&#x000a0;66.9 and 234.1&#x000a0;&#x000b1;&#x000a0;44.7, respectively (within-group <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 for both; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). However, at 6&#x000a0;months, SF-36 scales were significantly higher in the CPVI group than in the ADT group, as were the PCS scores (269.3&#x000a0;&#x000b1;&#x000a0;58.6 vs. 234.9&#x000a0;&#x000b1;&#x000a0;66.9; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and MCS scores (273.6&#x000a0;&#x000b1;&#x000a0;69.4 vs. 234.1&#x000a0;&#x000b1;&#x000a0;44.7; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>The mean changes from baseline to 6-months for the SF-36 scales</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">CPVI</th><th align="left" rowspan="2">
<italic>P</italic>
</th><th align="left" colspan="2">ADT</th><th align="left" rowspan="2">
<italic>P</italic>
</th></tr><tr><th align="left">Baseline<break/>
<bold>Mean&#x000a0;&#x000b1;&#x000a0;SD</bold>
</th><th align="left">6-months<break/>
<bold>Mean&#x000a0;&#x000b1;&#x000a0;SD</bold>
</th><th align="left">Baseline<break/>
<bold>Mean&#x000a0;&#x000b1;&#x000a0;SD</bold>
</th><th align="left">6-months<break/>
<bold>Mean&#x000a0;&#x000b1;&#x000a0;SD</bold>
</th></tr></thead><tbody><tr><td align="left">PF</td><td char="&#x000b1;" align="char">67.1&#x000a0;&#x000b1;&#x000a0;17.9</td><td char="&#x000b1;" align="char">76.0&#x000a0;&#x000b1;&#x000a0;17.5</td><td char="." align="char">0.005</td><td char="&#x000b1;" align="char">62.1&#x000a0;&#x000b1;&#x000a0;26.3</td><td char="&#x000b1;" align="char">65.1&#x000a0;&#x000b1;&#x000a0;20.4</td><td char="." align="char">0.494</td></tr><tr><td align="left">RP</td><td char="&#x000b1;" align="char">46.9&#x000a0;&#x000b1;&#x000a0;17.6</td><td char="&#x000b1;" align="char">58.0&#x000a0;&#x000b1;&#x000a0;22.9</td><td char="." align="char">0.002</td><td char="&#x000b1;" align="char">42.5&#x000a0;&#x000b1;&#x000a0;20.6</td><td char="&#x000b1;" align="char">48.9&#x000a0;&#x000b1;&#x000a0;26.9</td><td char="." align="char">0.174</td></tr><tr><td align="left">BP</td><td char="&#x000b1;" align="char">58.6&#x000a0;&#x000b1;&#x000a0;24.0</td><td char="&#x000b1;" align="char">69.3&#x000a0;&#x000b1;&#x000a0;21.2</td><td char="." align="char">0.007</td><td char="&#x000b1;" align="char">60.6&#x000a0;&#x000b1;&#x000a0;20.3</td><td char="&#x000b1;" align="char">66.8&#x000a0;&#x000b1;&#x000a0;22.2</td><td char="." align="char">0.120</td></tr><tr><td align="left">GH</td><td char="&#x000b1;" align="char">48.2&#x000a0;&#x000b1;&#x000a0;20.7</td><td char="&#x000b1;" align="char">66.0&#x000a0;&#x000b1;&#x000a0;19.9</td><td char="." align="char">&#x0003c;0.001</td><td char="&#x000b1;" align="char">42.9&#x000a0;&#x000b1;&#x000a0;25.5</td><td char="&#x000b1;" align="char">52.2&#x000a0;&#x000b1;&#x000a0;26.8</td><td char="." align="char">0.023</td></tr><tr><td align="left">VT</td><td char="&#x000b1;" align="char">60.9&#x000a0;&#x000b1;&#x000a0;16.5</td><td char="&#x000b1;" align="char">70.8&#x000a0;&#x000b1;&#x000a0;20.3</td><td char="." align="char">0.003</td><td char="&#x000b1;" align="char">57.4&#x000a0;&#x000b1;&#x000a0;17.5</td><td char="&#x000b1;" align="char">62.8&#x000a0;&#x000b1;&#x000a0;13.2</td><td char="." align="char">0.062</td></tr><tr><td align="left">SF</td><td char="&#x000b1;" align="char">56.4&#x000a0;&#x000b1;&#x000a0;21.1</td><td char="&#x000b1;" align="char">70.1&#x000a0;&#x000b1;&#x000a0;24.3</td><td char="." align="char">0.001</td><td char="&#x000b1;" align="char">53.3&#x000a0;&#x000b1;&#x000a0;17.3</td><td char="&#x000b1;" align="char">60.5&#x000a0;&#x000b1;&#x000a0;17.7</td><td char="." align="char">0.030</td></tr><tr><td align="left">MH</td><td char="&#x000b1;" align="char">60.8&#x000a0;&#x000b1;&#x000a0;15.9</td><td char="&#x000b1;" align="char">72.4&#x000a0;&#x000b1;&#x000a0;16.4</td><td char="." align="char">&#x0003c;0.001</td><td char="&#x000b1;" align="char">60.1&#x000a0;&#x000b1;&#x000a0;11.2</td><td char="&#x000b1;" align="char">62.3&#x000a0;&#x000b1;&#x000a0;12.2</td><td char="." align="char">0.324</td></tr><tr><td align="left">RE</td><td char="&#x000b1;" align="char">50.0&#x000a0;&#x000b1;&#x000a0;25.0</td><td char="&#x000b1;" align="char">60.4&#x000a0;&#x000b1;&#x000a0;26.1</td><td char="." align="char">0.021</td><td char="&#x000b1;" align="char">42.7&#x000a0;&#x000b1;&#x000a0;25.8</td><td char="&#x000b1;" align="char">48.4&#x000a0;&#x000b1;&#x000a0;27.4</td><td char="." align="char">0.255</td></tr><tr><td align="left">PCS</td><td char="&#x000b1;" align="char">220.8&#x000a0;&#x000b1;&#x000a0;54.6</td><td char="&#x000b1;" align="char">269.3&#x000a0;&#x000b1;&#x000a0;58.6</td><td char="." align="char">&#x0003c;0.001</td><td char="&#x000b1;" align="char">208.2&#x000a0;&#x000b1;&#x000a0;64.9</td><td char="&#x000b1;" align="char">234.9&#x000a0;&#x000b1;&#x000a0;66.9</td><td char="." align="char">0.033</td></tr><tr><td align="left">MCS</td><td char="&#x000b1;" align="char">228.1&#x000a0;&#x000b1;&#x000a0;54.3</td><td char="&#x000b1;" align="char">273.6&#x000a0;&#x000b1;&#x000a0;69.4</td><td char="." align="char">&#x0003c;0.001</td><td char="&#x000b1;" align="char">213.5&#x000a0;&#x000b1;&#x000a0;44.5</td><td char="&#x000b1;" align="char">234.1&#x000a0;&#x000b1;&#x000a0;44.7</td><td char="." align="char">0.015</td></tr></tbody></table><table-wrap-foot><p>
<italic>ADT</italic> antiarrhythmic drug therapy, <italic>BP</italic> bodily pain, <italic>CPVI</italic> circumferential pulmonary vein isolation, <italic>GH</italic> general health perception, <italic>MCS</italic> mental component summary, <italic>MH</italic> mental health, <italic>PCS</italic> physical component summary, <italic>PF</italic> physical functioning, <italic>RE</italic> role limitations due to emotional problems, <italic>RP</italic> role limitations due to physical problems, <italic>VT</italic> vitality, <italic>SF</italic> social functioning</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>The mean changes of each group for the SF-36 scales</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">CPVI<break/>
<bold>Mean&#x000a0;&#x000b1;&#x000a0;SD</bold>
</th><th align="left">ADT<break/>
<bold>Mean&#x000a0;&#x000b1;&#x000a0;SD</bold>
</th><th align="left">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">PF</td><td char="&#x000b1;" align="char">76.0&#x000a0;&#x000b1;&#x000a0;17.5</td><td char="&#x000b1;" align="char">65.1&#x000a0;&#x000b1;&#x000a0;20.4</td><td char="." align="char">0.002</td></tr><tr><td align="left">RP</td><td char="&#x000b1;" align="char">58.0&#x000a0;&#x000b1;&#x000a0;22.9</td><td char="&#x000b1;" align="char">48.9&#x000a0;&#x000b1;&#x000a0;26.9</td><td char="." align="char">0.041</td></tr><tr><td align="left">BP</td><td char="&#x000b1;" align="char">69.3&#x000a0;&#x000b1;&#x000a0;21.2</td><td char="&#x000b1;" align="char">66.8&#x000a0;&#x000b1;&#x000a0;22.2</td><td char="." align="char">0.528</td></tr><tr><td align="left">GH</td><td char="&#x000b1;" align="char">66.0&#x000a0;&#x000b1;&#x000a0;19.9</td><td char="&#x000b1;" align="char">52.2&#x000a0;&#x000b1;&#x000a0;26.8</td><td char="." align="char">0.007</td></tr><tr><td align="left">VT</td><td char="&#x000b1;" align="char">70.8&#x000a0;&#x000b1;&#x000a0;20.3</td><td char="&#x000b1;" align="char">62.8&#x000a0;&#x000b1;&#x000a0;13.2</td><td char="." align="char">0.010</td></tr><tr><td align="left">SF</td><td char="&#x000b1;" align="char">70.1&#x000a0;&#x000b1;&#x000a0;24.3</td><td char="&#x000b1;" align="char">60.5&#x000a0;&#x000b1;&#x000a0;17.7</td><td char="." align="char">0.013</td></tr><tr><td align="left">MH</td><td char="&#x000b1;" align="char">72.4&#x000a0;&#x000b1;&#x000a0;16.4</td><td char="&#x000b1;" align="char">62.3&#x000a0;&#x000b1;&#x000a0;12.2</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td align="left">RE</td><td char="&#x000b1;" align="char">60.4&#x000a0;&#x000b1;&#x000a0;26.1</td><td char="&#x000b1;" align="char">48.4&#x000a0;&#x000b1;&#x000a0;27.4</td><td char="." align="char">0.015</td></tr><tr><td align="left">PCS</td><td char="&#x000b1;" align="char">269.3&#x000a0;&#x000b1;&#x000a0;58.6</td><td char="&#x000b1;" align="char">234.9&#x000a0;&#x000b1;&#x000a0;66.9</td><td char="." align="char">0.003</td></tr><tr><td align="left">MCS</td><td char="&#x000b1;" align="char">273.6&#x000a0;&#x000b1;&#x000a0;69.4</td><td char="&#x000b1;" align="char">234.1&#x000a0;&#x000b1;&#x000a0;44.7</td><td char="." align="char">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>
<italic>ADT</italic> antiarrhythmic drug therapy, <italic>BP</italic> bodily pain, <italic>CPVI</italic> circumferential pulmonary vein isolation, <italic>GH</italic> general health perception, <italic>MCS</italic> mental component summary, <italic>MH</italic> mental health, <italic>PCS</italic> physical component summary, <italic>PF</italic> physical functioning, <italic>RE</italic> role limitations due to emotional problems, <italic>RP</italic> role limitations due to physical problems, <italic>VT</italic> vitality, <italic>SF</italic> social functioning</p></table-wrap-foot></table-wrap></p><p>Patients in the CPVI group were further evaluated based on whether they had AF recurrence. Among patients who had no AF recurrence, the difference in all eight SF-36 scale measurements was statistically significant between the baseline and 6-month evaluations. Whereas the difference in all eight SF-36 scale measurements in patients with AF recurrence was statistically insignificant, except for the role limitations due to emotional problems.</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>AF is the most common chronic arrhythmia associated with an adverse prognosis. It is an independent risk factor for stroke, resulting in an approximate three- to fivefold excess risk [<xref ref-type="bibr" rid="CR2">2</xref>]. Furthermore, the risks attributable to most stroke risk factors decline with advancing age [<xref ref-type="bibr" rid="CR2">2</xref>]. AF causes disabling symptoms such as fatigue, dyspnea, and palpitations. As a result, the patient&#x02019;s QoL may be drastically reduced. The study showed that AF was associated with a 1.5&#x02013;1.9-fold increased risk of mortality and was an independent predictor of mortality with stroke [<xref ref-type="bibr" rid="CR3">3</xref>]. At present, more attention is focused on the research and treatment of AF in order to improve the QoL of patients with this disorder.</p><p>This study demonstrated that the SF-36 scales were significantly higher in patients treated with CPVI compared to ADT for all physical and mental health assessments except for body pain. The results of the present study indicate that compared with ADT, CPVI is more likely to maintain sinus rhythm, reduce dyspnea, palpitations, and stroke, and improve the QoL of AF patients.</p><p>In two previous trials, radiofrequency catheter ablation appeared superior to ADT treatment in improving symptoms and QoL [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], which concurs with the present study. The results of a multicenter trial comparing catheter ablation with ADT in patients with symptomatic, paroxysmal AF refractory to one or more drugs showed the clear superiority of ablation on rhythm-related endpoints [<xref ref-type="bibr" rid="CR5">5</xref>]. A different multicenter clinical trial that evaluated symptoms and QoL comparing catheter ablation with ADT as a second-line treatment for patients with paroxysmal AF concluded that ablation is superior to ADT at improving symptoms and QoL [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>The results from a recent study by Wokhlu et al. [<xref ref-type="bibr" rid="CR7">7</xref>] which enrolled 323 patients, showed that 72% of patients achieved AF elimination off ADT, 15% achieved AF control on ADT, and 13% had recurrent AF after 2&#x000a0;years of follow-up. The PCS and MCS scores also showed a noteworthy increase. The results of several trials have shown that radiofrequency catheter ablation is superior to ADT at maintaining sinus rhythm, primarily as a second-line treatment [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. In the present study, after a mean follow-up of 12.7&#x000a0;&#x000b1;&#x000a0;4.3&#x000a0;months, 22.8% and 62.1% of the ADT group and CPVI group, respectively, had no recurrence of AF. At 6&#x000a0;month, the PCS and MCS scores increased considerably in both the CPVI group and the ADT group. CPVI has a higher success rate and, thus, results in an elevated QoL.</p><p>The results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study [<xref ref-type="bibr" rid="CR12">12</xref>] showed that there were no differences in survival or event rates in patients with AF randomized either to ventricular rate control or heart rhythm control. The QoL scores were comparable between the rate control and rhythm control interventions. In addition, QoL was similar with sinus rhythm versus AF control. Attempts to improve QoL by restoring sinus rhythm were usually unsuccessful [<xref ref-type="bibr" rid="CR12">12</xref>]. A multicenter trial demonstrated that a routine strategy of heart rhythm control such as metoprolol or amiodarone does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy [<xref ref-type="bibr" rid="CR13">13</xref>]. In previous studies, the restoration and maintenance of sinus rhythm were often attempted with electrical cardioversion and ADT. However, the favorable outcome acquired by restoring the sinus rhythm was counteracted by the increased risk of adverse effects from ADT. In this study, patients in the CPVI group were sorted into two groups based on AF recurrence: no AF recurrence group and AF recurrence group. In the no AF recurrence group, there was a significant difference in all eight SF-36 scales, but there was no statistically significant difference in the recurrence AF group, except for role limitations due to emotional problems. AF impaired QoL and was related to increased frequency and duration of disease and disease indexes. The present results show that restoration and maintenance of sinus rhythm can improve the QoL.</p><p>The effect of ADT on the QoL of patients with AF is still controversial [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. A study by Dorian et al. [<xref ref-type="bibr" rid="CR14">14</xref>] has suggested that QoL improvements were not significantly different among the groups randomized to amiodarone, sotalol, or propafenone, and this was especially true for patients in whom treatment prevented AF recurrence. The study found that general health perception, social functioning, and physical and mental health summary measures of the SF-36 scales improved significantly from baseline to 6&#x000a0;months. Thus, indicating the lack of superiority of ADT over ablation in patients with AF with regard to maintenance of sinus rhythm and improvement in QoL.</p><p>In summary, CPVI is superior to ADT in patients with AF regarding the maintenance of sinus rhythm and improvement in QoL, especially in patients in whom CPVI was successful.</p></sec></body><back><ack><p>Dr. Xu is the guarantor for this article, and takes responsibility for the integrity of the work as a whole.</p><sec id="d30e1298"><title>Conflict of interest</title><p>The authors have no conflicts of interest.</p></sec><sec id="d30e1303"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1055</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00097-3</pub-id><pub-id pub-id-type="pmid">9817123</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Vaziri</surname><given-names>SM</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names></name><name><surname>Belanger</surname><given-names>AJ</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name></person-group><article-title>Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study</article-title><source>JAMA</source><year>1994</year><volume>271</volume><fpage>840</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1001/jama.1994.03510350050036</pub-id><pub-id pub-id-type="pmid">8114238</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jais</surname><given-names>P</given-names></name><name><surname>Cauchemez</surname><given-names>B</given-names></name><name><surname>Macle</surname><given-names>L</given-names></name><etal/></person-group><article-title>Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>2498</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.772582</pub-id><pub-id pub-id-type="pmid">19029470</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Impact of atrial fibrillation on the risk of death: the Framingham Heart Study</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>946</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.98.10.946</pub-id><pub-id pub-id-type="pmid">9737513</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilber</surname><given-names>DJ</given-names></name><name><surname>Pappone</surname><given-names>C</given-names></name><name><surname>Neuzil</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial</article-title><source>JAMA</source><year>2010</year><volume>303</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.2029</pub-id><pub-id pub-id-type="pmid">20103757</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>MR</given-names></name><name><surname>Walczak</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2010</year><volume>3</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.110.957563</pub-id><pub-id pub-id-type="pmid">20940250</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wokhlu</surname><given-names>A</given-names></name><name><surname>Monahan</surname><given-names>KH</given-names></name><name><surname>Hodge</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><fpage>2308</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.01.040</pub-id><pub-id pub-id-type="pmid">20488300</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weerasooriya</surname><given-names>R</given-names></name><name><surname>Jais</surname><given-names>P</given-names></name><name><surname>Hocini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of catheter ablation on quality of life of patients with paroxysmal atrial fibrillation</article-title><source>Heart Rhythm</source><year>2005</year><volume>2</volume><fpage>619</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2005.02.1037</pub-id><pub-id pub-id-type="pmid">15922270</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oral</surname><given-names>H</given-names></name><name><surname>Pappone</surname><given-names>C</given-names></name><name><surname>Chugh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Circumferential pulmonary-vein ablation for chronic atrial fibrillation</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>934</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050955</pub-id><pub-id pub-id-type="pmid">16510747</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappone</surname><given-names>C</given-names></name><name><surname>Augello</surname><given-names>G</given-names></name><name><surname>Sala</surname><given-names>S</given-names></name><etal/></person-group><article-title>Randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>2340</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2006.08.037</pub-id><pub-id pub-id-type="pmid">17161267</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forleo</surname><given-names>GB</given-names></name><name><surname>Mantica</surname><given-names>M</given-names></name><name><surname>De Luca</surname><given-names>L</given-names></name><etal/></person-group><article-title>Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy</article-title><source>J Cardiovasc Electrophysiol</source><year>2009</year><volume>20</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8167.2008.01275.x</pub-id><pub-id pub-id-type="pmid">18775050</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>LS</given-names></name><name><surname>Brodsky</surname><given-names>M</given-names></name><name><surname>Schron</surname><given-names>E</given-names></name><etal/></person-group><article-title>Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study</article-title><source>Am Heart J</source><year>2005</year><volume>149</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2004.03.065</pub-id><pub-id pub-id-type="pmid">15660042</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>D</given-names></name><name><surname>Talajic</surname><given-names>M</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rhythm control versus rate control for atrial fibrillation and heart failure</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2667</fpage><lpage>2677</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0708789</pub-id><pub-id pub-id-type="pmid">18565859</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorian</surname><given-names>P</given-names></name><name><surname>Paquette</surname><given-names>M</given-names></name><name><surname>Newman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation</article-title><source>Am Heart J</source><year>2002</year><volume>143</volume><fpage>984</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1067/mhj.2002.122518</pub-id><pub-id pub-id-type="pmid">12075253</pub-id></element-citation></ref></ref-list></back></article>